Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Cardurion Pharmaceuticals is raising $300,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Peter Lawrence played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cardurion Pharmaceuticals
Cardurion is a clinical-stage cardiovascular biotechnology company developing new therapeutics for the treatment of heart failure and cardiovascular diseases. Cardurions product pipeline includes our lead clinical asset, CRD-733, a PDE-9 inhibitor with the potential to improve cardiac function in heart failure patients. Cardurion has an exclusive licensing agreement with Astellas for the development and commercialization of CRD-733. Additionally, Cardurion has a strong cardiovascular development partnership with Takeda which is fueling drug discovery and preclinical development work being conducted in our internal research laboratories.

To learn more about Cardurion Pharmaceuticals, visit http://cardurion.com/

Contact:
Peter Lawrence, Chief Executive Officer
617-996-1433

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved